Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 4/20 | 0.37 |
| ▸ | THRA | P10827 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981285 | 0.90 | EGLN1 (0.38) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL4300846 | 0.80 | MAPT (0.47) | EGLN1THRBTHRATP53MAPT | |
| SCHEMBL4263531 | 0.80 | MAPT (0.43) | EGLN1TP53MAPTSMN1; SMN2SCD | |
| SCHEMBL3984721 | 0.77 | KMT2A (0.38) | THRBTHRATP53MAPTSMN1; SMN2 | |
| SCHEMBL3980253 | 0.75 | EGLN1 (0.40) | EGLN1THRBTHRAHIF1A | |
| SCHEMBL3985293 | 0.72 | SMN1; SMN2 (0.39) | THRBTHRATP53MAPTSMN1; SMN2 | |
| SCHEMBL4295203 | 0.71 | THRB (0.34) | THRBTHRA | |
| SCHEMBL3990474 | 0.70 | KDM4E (0.47) | EGLN1THRBMAPTSMN1; SMN2HIF1A | |
| SCHEMBL4347525 | 0.70 | THRB (0.49) | THRBTHRAHIF1A | |
| SCHEMBL4523898 | 0.69 | MAPT (0.55) | MAPTSMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-2024336-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128492-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | EGLN1 2905/4885THRB 5/4885THRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.